Versed
PreclinicalSmall molecule
Versed is one of 11 small molecule programs targeting Ventricular Tachycardia. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Ventricular Tachycardia
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Tambocor
AAlvogen Korea
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Coreg
Akero TherapeuticsApproved
Calan
VVal Adams
Approved
Mexitil
Boehringer IngelheimApproved
Duragesic
CCephalon
Preclinical
Betapace
LLegacy Health System
Preclinical
Guideline Directed Medical Therapy
IIRCCS Policlinico S. Donato
Preclinical
Versed
EEmory University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ventricular Tachycardia1 trial
Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia
Completed·—·N/A·NCT02419547·11 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Versed. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- EEmory University